Kyverna Therapeutics (KYTX) EBT (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of EBT data on file, last reported at -$39.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 10.99% year-over-year to -$39.7 million; the trailing twelve-month figure through Mar 2026 stood at -$156.3 million (down 7.56% YoY), and the FY2025 full-year result was -$161.2 million, down 26.56% from the prior year.
• EBT for Q1 2026 stood at -$39.7 million, down from -$37.8 million in the prior quarter.
• Across five years, EBT topped out at -$11.1 million in Q1 2023 and bottomed at -$44.6 million in Q1 2025.
• The 4-year median for EBT is -$34.4 million (2024), against an average of -$29.9 million.
• The widest annual swing landed in 2024, when EBT sank 139.38%; it then advanced 10.99% in 2026.
• A 4-year view of EBT shows it stood at -$20.6 million in 2023, then sank by 81.7% to -$37.5 million in 2024, then dropped by 0.87% to -$37.8 million in 2025, then fell by 4.99% to -$39.7 million in 2026.
• The last three EBT figures came in at -$39.7 million (Q1 2026), -$37.8 million (Q4 2025), and -$36.7 million (Q3 2025), per Business Quant data.

Peer Comparison